⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

April 9, 2024Neurology

Cerebrospinal Fluid and Plasma Concentrations of Ubrogepant in Participants with a History of Migraine (P5-12.008)

Ramesh Boinpally Joel M. Trugman

View Full Paper

Ask AI

Bookmark

Share

Abstract

To determine the cerebrospinal fluid (CSF) to plasma concentration ratio of ubrogepant in participants with a history of migraine.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Boinpally et al. (2024) studied this question.

synapsesocial.com/papers/68e6fdb8b6db643587678234 https://doi.org/10.1212/wnl.0000000000205691

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Ubrogepant Plasma and Cerebrospinal Fluid Exposures in Participants With a History of Migraine: Findings From a Phase 1b Open‐Label TrialHuman Clinical Trial · 2026 · 2 citations
2Effect of Ubrogepant on Patient-Reported Outcomes When Administered During the Migraine Prodrome2024 · 2 citations
3Population Pharmacokinetics and Exposure‐Response Analyses for Ubrogepant Efficacy and Safety in the Acute Treatment of Migraine: Analysis of Phase 1–3 StudiesLate-Phase Clinical Trial · 2026
4A Case of Acute Migraine Without Aura Treated With a New FDA-Approved Medication Ubrogepant2024 · 1 citations
5Safety and tolerability of ubrogepant for the acute treatment of migraine in participants taking atogepant for the preventive treatment of episodic migraine: Results from the TANDEM studyLate-Phase Clinical Trial · 2024 · 13 citations